Johns Hopkins built a tool. The tool did math. The math says the 2025 U.S. measles outbreak cost more than $37 million.
Researchers now have a calculator for disease. Congratulations to everyone involved.
Consider the figure. Thirty-seven million dollars. That is roughly what a mid-tier hedge fund spends on a Bloomberg terminal and a sense of destiny.
The tool exists so officials can price an outbreak while it happens. Hospitals, health departments, and school districts get a number. Nobody gets a vaccine from the number. But the spreadsheet looks great.
Here is what bothers me. We needed a Johns Hopkins tool to learn that a contagious disease is expensive. A disease that was declared eliminated in the U.S. in 2000. A disease with a vaccine older than the Rubik's Cube. Somebody ran the numbers on a problem we solved, then unsolved, then billed.
Retail traders will read this and look for the ticker. They will buy anything with "vaccine" in the name and sell it the second a podcast tells them to. Some guy in Ohio has already put his rent into a company that makes tongue depressors.
Let me save you the research. Measles does not trade. It has no earnings call. It has no guidance. It has a 90 to 95 percent preventable rate if you show up for two shots, which is more commitment than your average day trader gives to a stop-loss.
Prediction: the tool will be accurate, the number will grow, and someone will still ask if it is bullish.
Thirty-seven million dollars buys a lot of MMR shots. Instead it bought a PDF.

Leave a Comment